Complete FDA and NHTSA recall records dated in 2025, organized for browsing by month, category and recalling company.
Select a month to review the recall records reported during that period.
Records are ordered by the best available source date.
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred…
Defective container: cracked/broken cartridges
Subpotent product:out of specification assay results observed during long term stability testing.
Contaminated with Salmonella
Clostridium botulinum (uneviscerated fish)
Contaminated with Salmonella
Undeclared Milk and FD&C Blue #1.
Clostridium botulinum (uneviscerated fish)
Foreign object
Nissan North America, Inc. (Nissan) is recalling certain 2026 Rogue vehicles. The incorrect-size spare tire may have been installed, which does not match the tire size and inflation…
Chrysler (FCA US, LLC) is recalling certain 2025 Ram 2500 Pickup, 3500 Pickup, 3500 Cab Chassis, 4500 Cab Chassis, and 5500 Cab Chassis trucks. A software error in the occupant restraint…
Vantage Mobility, LLC (VM) is recalling certain 2021-2026 Honda Odyssey, 2021-2025 Chrysler Pacifica, and Toyota Sienna vehicles equipped with QRT-Deluxe and QRT-Max wheelchair restraints.…
Rollx Vans (Rollx) is recalling certain GMC Yukon, Sierra, Chevrolet Express 2500, Ford Transit, E-250, Toyota Sienna, Sienna Hybrid, Honda Odyssey, Chrysler Town and Country, Voyager,…
Kia America, Inc. (Kia) is recalling certain 2023-2025 Sportage Plug-In Hybrid Electric (PHEV) and 2024-2025 Sportage vehicles equipped with a 4.2" screen and a Genuine Kia tow hitch…
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Failed stability specifications: Out of specification for hardness test
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.
Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.
Failed stability specifications: Out of specification for hardness test
Clostridium botulinum (uneviscerated fish)
Undeclared Soy Protein Concentrate
This archive groups records by their reported or recall date. It does not imply that every recall was initiated, announced and resolved during the same calendar year. Open the individual record for the exact dates and source details supplied by FDA or NHTSA.
